
Next-generation technologies will be based on smell
Scientists and entrepreneurs are increasingly turning to scent to help detect disease, boost memory, entertain, and protect people from food allergies.

A brilliant solution has been developed by Weizmann Institute of Science professor, Yonina Eldar
A brilliant solution has been developed by Weizmann Institute of Science professor, Yonina Eldar, and her team for Ultrasound Localization Microscopy (ULM) to aid in the early detection of microvascular changes, signaling diseases such as malignant tumors, inflammatory diseases, as well as myocardial and brain disorders.

Phytolon, is emerging as an important player in the food dye market
Phytolon’s proprietary technology provides healthy, efficient, and sustainable natural food-coloring alternatives to azo/synthetic dyes used in food and beverages.

In a major advance for IBD sufferers, Yeda spinoff BiomX Inc is now collaborating with Boehringer Ingelheim
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Yeda's Newsletter - June 2022
In the first half of 2022, Yeda has commercialized technologies from a broad range of disciplines at the Weizmann Institute, by partnering with existing companies as well as newly-established startups.

Quantum Source Goes Out of Stealth to Enable Useful Photonic Quantum Computers with Millions of Qubits
Three serial entrepreneurs and a leading Professor from the Weizmann Institute of Science join forces to establish Quantum Source and actualize a breakthrough technology that will enable photonic quantum computers that are 50,000x more efficient than state-of-the-art implementations.

Yeda Subsidiary Start-Ups Make Headlines Worldwide
Yeda spinoffs operate in a wide range of fields, from agriculture and plant genetics to diagnostics, nanotechnology and pharmaceuticals. Their activities, research and collaborations are often covered by the local and global press. The following is a small sample of publications that have recently featured innovative Yeda start-ups that leverage knowledge and technologies developed by the Weizmann Institute of Science.

Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda
Lysogene announced today that it has exercised its option to enter into an exclusive worldwide license agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, for the development and commercialization of a gene therapy candidate for the treatment of neuronopathic Gaucher disease and Parkinson disease (PD) with GBA1 mutations.

Yeda @ Bio 2022
Yeda is Coming to #BIO2022!
Come and meet Yeda at the upcoming BIO International Convention in San Diego! Elik Chapnik and Yael Klionsky will be presenting a wide range of our biopharma and diagnostic technologies.

Viruses in Service of Man - Fight Against Bacterial Diseases in Agriculture (Hebrew)
Citrus fruits, delicious, healthy and full of Zionism, but also exposed to many hazards
Pages
